Company profile
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

Pipeline4 assets

  • PraliciguatsGC / soluble guanylate cyclase stimulator / Kidney disease
    Focal segmental glomerulosclerosisPhase 2first patient enrolled Dec 2025
  • Ebribafusp alfaAKB-097 / C3d/factor H / anti-C3d-factor H fusion protein; complement inhibitor / Rare kidney diseases
    IgA nephropathyPhase 2 plannedbasket trial planned 2H 2026Lupus nephritisPhase 2 plannedbasket trial planned 2H 2026C3 glomerulopathyPhase 2 plannedbasket trial planned 2H 2026
  • AKB-9090AKB-9090 / HIF-PH / HIF-PH inhibitor / Kidney disease; acute care
    Cardiac surgery-associated acute kidney injuryPhase 1first participants dosed Apr 2026Acute respiratory distress syndromePreclinical
  • AKB-10108AKB-10108 / HIF-PH / HIF-PH inhibitor / Other disease areas
    Retinopathy of prematurityPreclinical

Latest news17 items

All news

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on

Trial ResultsInterim analysis results Tue, Jun 30, 2026, 8:00 AM EDT

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Additional Orange Book Listed Patent Secured and Composition of Matter Patent is Eligible for 5-Year Extension CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Peer-reviewed publication in prominent nephrology journal reinforces clinical differentiation of Vafseo® (vadadustat) in dialysis-dependent CKD anemia CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better

Akebia Therapeutics, Inc. • Endpoint Arena